NovoCure (NVCR) Cash & Current Investments (2014 - 2026)

NovoCure (NVCR) has reported Cash & Current Investments for 13 consecutive years, with $440.6 million the latest figure, recorded in Q2 2026.

• Quarterly Cash & Current Investments fell 51.67% year-over-year to $440.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $440.6 million (down 51.67% YoY) and the FY2025 annual result came in at $447.7 million, down 53.36% from the prior year.
• Cash & Current Investments rose to $440.6 million in Q2 2026 per NVCR's latest filing, from $432.0 million in the prior quarter.
• Over the last five years, Cash & Current Investments for NVCR reached as high as $1.0 billion in Q3 2025 and fell as low as $432.0 million in Q1 2026.
• A 5-year average of $860.4 million and a median of $936.6 million in 2022 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2022 — Cash & Current Investments rose 7.86% — and 2026, when it slumped 53.5%.
• Year by year, Cash & Current Investments stood at $969.4 million in 2022, then retreated by 6.07% to $910.6 million in 2023, then climbed by 5.41% to $959.9 million in 2024, then plunged by 53.36% to $447.7 million in 2025, then dropped by 1.59% to $440.6 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $440.6 million, $432.0 million, and $447.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.